Hemophilia Drug Prior Authorization

 

Effective July 1, 2019, Prior Authorization for hemophilia products will be required for groups with carved-in pharmacy benefits that participate in Utilization Management.  Magellan Rx will perform the drug reviews for Prior Authorization (PA) based on new policy criteria.  The PA reviews will ensure that optimal dosing and products are being prescribed.

Additionally, Magellan Rx will provide oversight of specialty pharmacy dispensing as part of this program.  Specialty pharmacies dispensing the hemophilia drugs will also be required to obtain Hemophilia Dose Authorizations from Magellan Rx prior to dispensing the drug.  For more information on hemophilia management, please call 800-424-7892.